contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Scandinavian Medical Solutions is a Danish-based trading company specialized in purchase and resale of used diagnostic imaging equipment such as CT scanners and MR scanners of high quality. Scandinavian Medical Solutions is specialized in offering flexible solutions for customers with specific demands, which is often a better and cheaper alternative to a new and more expensive produced OEM-equipment.

Scandinavian Medical Solutions was founded in 2018, and the company has been listed at Nasdaq First North in Denmark since November 2021.

Scandinavian Medical Solutions

Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients.

Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma

Danske Bank was founded in 1871 and is Denmark’s largest bank, with headquarters in Copenhagen and activities in Denmark, Sweden, Norway, Finland, Northern Ireland, and the United Kingdom. Danske Bank is engaged in providing payment services, trading in securities and other instruments, depositing of surplus liquidity and the provision of short- and long-term financing. It operates four commercial business units Personal & Business Customers, Large Corporates & Institutions, Danica Pension, and Northern Ireland.

The Personal & Business Customers segment provides advisory services to personal customers, Private Banking customers and small and medium-sized businesses in Denmark, Sweden, Norway and Finland. Its Large Corporates & Institutions segment is engaged with providing strategic advice, financial solutions and products to large Nordic and institutional customers. Danica Pension provides pension services within Denmark, and in its Northern Ireland segment, Danske Bank serves personal business and corporate customers in Northern Ireland with some activities in targeted sectors across the rest of the United Kingdom.

In 2021 Danske Bank’s market share in Denmark was 25% in lending and 29% in deposits.

Danske Bank

Tryg A/S is a diversified Danish-based insurance company operating in multiple segments, including private, commercial and corporate. Tryg is listed on the Nasdaq OMX Copenhagen Stock Exchange and is a member of the OMX C25 index.

Tryg is the largest non-life insurance company in Scandinavia, with a leading market position in Denmark and top 3 positions in Norway and Sweden after acquiring Codan in Norway and Trygg-Hansa in Sweden. Tryg services over 5 million customers throughout its active markets and revenue is mainly driven through its Private insurance segment.

Its private segments sell non-life insurance products, such as motor, home, travel, etc to private individuals in Denmark, Sweden and Norway. Its commercial segment sells insurance products to small and medium-sized companies in Denmark, Norway & Sweden. In contrast, its corporate segment sells insurance products to larger corporate clients in the same regions.

Tryg

Scandinavian Medical Solutions - Opjusterede i g&aring;r forventningerne til b&aring;de oms&aelig;tning og EBITDA for regnskabs&aring;ret 2022/2023, som f&oslash;lge af st&oslash;rre eftersp&oslash;rgsel efter udlejningsl&oslash;sninger og reservedele. Ydermere har de i den seneste tid oplevet flere store salg med h&oslash;j profitmargin, som har p&aring;virket selskabets oms&aelig;tning positivt. Opjusteringen er selskabets tredje i &aring;r. L&aelig;s mere her: <a href="https://www.inderes.dk/analyst-comments/scandinavian-medical-solutions-opjusterer-forventningerne-for-tredje-gang-i-ar" target="_blank" rel="noopener">https://www.inderes.dk/analyst-comments/scandinavian-medical-solutions-opjusterer-forventningerne-for-tredje-gang-i-ar</a>
Hansa Biopharma - Regulatory milestone marks the first time Idefirix has been approved in kidney transplantation from both living and deceased donors. Hansa Biopharma announced today that the Australian Therapeutic Goods Administration (&ldquo;TGA&rdquo;) has provisionally approved Idefirix (imlifidase) as desensitization treatment for highly sensitized patients prior to kidney transplantation from both living and deceased donors. The provisional approval has a duration of two years and was based on data from their phase 2 studies, that included highly sensitized patients who received a kidney from either a living (17%) or deceased donor (83%) following desensitization treatment with imlifidase. Read full story here:<a href="https://www.hansabiopharma.com/media/press-releases/2023/idefirix-imlifidase-receives-provisional-approval-in-australia-as-desensitization-treatment-in-highly-sensitized-patients-prior-to-kidney-transplantation/" target="_blank" rel="noopener">https://www.hansabiopharma.com/media/press-releases/2023/idefirix-imlifidase-receives-provisional-approval-in-australia-as-desensitization-treatment-in-highly-sensitized-patients-prior-to-kidney-transplantation/</a>
We host an event with Hansa Biopharma Thursday the 20th of July at 11 AM CEST - sign up here: <a href="https://www.inderes.dk/videos/hansa-biopharma-presentation-of-half-year-report-2023" target="_blank" rel="noopener">https://www.inderes.dk/videos/hansa-biopharma-presentation-of-half-year-report-2023</a>
Danske Bank - Mediobanca fastholder sit target p&aring; DKK 170 inden regnskabet men s&aelig;nker anbefalingen fra neutral til underperform.
Tryg - Efter regnskabet i g&aring;r har flere banker &aelig;ndret deres anbefaling og target. Berenberg fastholder k&oslash;b men s&aelig;nker target fra DKK 195 til DKK 175. Citigroup &aelig;ndrer sin anbefaling fra neutral til k&oslash;b og s&aelig;nker target fra DKK 155,80 til 150,5.
Disclaimer:&nbsp;HC Andersen Capital modtager betaling fra selskaberne for en Digital IR aftale. Claus Thestrup - 12/07-2023 kl. 09:10

Dagens aktienyheder 12/07-2023

Login required

Stay up to date